344 related articles for article (PubMed ID: 30902060)
1. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.
Startin CM; Ashton NJ; Hamburg S; Hithersay R; Wiseman FK; Mok KY; Hardy J; Lleó A; Lovestone S; Parnetti L; Zetterberg H; Hye A; ; Strydom A
Alzheimers Res Ther; 2019 Mar; 11(1):26. PubMed ID: 30902060
[TBL] [Abstract][Full Text] [Related]
2. Composite Scores of Plasma Tau and β-Amyloids Correlate with Dementia in Down Syndrome.
Fang WQ; Hwu WL; Chien YH; Yang SY; Chieh JJ; Chang LM; Huang AC; Lee NC; Chiu MJ
ACS Chem Neurosci; 2020 Jan; 11(2):191-196. PubMed ID: 31799825
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase.
Mengel D; Liu W; Glynn RJ; Selkoe DJ; Strydom A; Lai F; Rosas HD; Torres A; Patsiogiannis V; Skotko B; Walsh DM
Alzheimers Res Ther; 2020 Mar; 12(1):27. PubMed ID: 32192521
[TBL] [Abstract][Full Text] [Related]
4. Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta-analyses.
Alhajraf F; Ness D; Hye A; Strydom A
Dev Neurobiol; 2019 Jul; 79(7):684-698. PubMed ID: 31389176
[TBL] [Abstract][Full Text] [Related]
5. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
[TBL] [Abstract][Full Text] [Related]
6. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
[TBL] [Abstract][Full Text] [Related]
7. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
[TBL] [Abstract][Full Text] [Related]
8. Increased amyloid beta protein levels in children and adolescents with Down syndrome.
Mehta PD; Capone G; Jewell A; Freedland RL
J Neurol Sci; 2007 Mar; 254(1-2):22-7. PubMed ID: 17275850
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.
Honig LS; Kang MS; Lee AJ; Reyes-Dumeyer D; Piriz A; Soriano B; Franco Y; Coronado ZD; Recio P; Mejía DR; Medrano M; Lantigua RA; Teich AF; Dage JL; Mayeux R
JAMA Netw Open; 2023 Apr; 6(4):e238214. PubMed ID: 37079306
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
Fagan AM; Henson RL; Li Y; Boerwinkle AH; Xiong C; Bateman RJ; Goate A; Ances BM; Doran E; Christian BT; Lai F; Rosas HD; Schupf N; Krinsky-McHale S; Silverman W; Lee JH; Klunk WE; Handen BL; Allegri RF; Chhatwal JP; Day GS; Graff-Radford NR; Jucker M; Levin J; Martins RN; Masters CL; Mori H; Mummery CJ; Niimi Y; Ringman JM; Salloway S; Schofield PR; Shoji M; Lott IT; ;
Lancet Neurol; 2021 Aug; 20(8):615-626. PubMed ID: 34302786
[TBL] [Abstract][Full Text] [Related]
11. Change in plasma Aß peptides and onset of dementia in adults with Down syndrome.
Schupf N; Zigman WB; Tang MX; Pang D; Mayeux R; Mehta P; Silverman W
Neurology; 2010 Nov; 75(18):1639-44. PubMed ID: 21041786
[TBL] [Abstract][Full Text] [Related]
12. Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease.
Shi Y; Lu X; Zhang L; Shu H; Gu L; Wang Z; Gao L; Zhu J; Zhang H; Zhou D; Zhang Z
ACS Chem Neurosci; 2019 Aug; 10(8):3479-3485. PubMed ID: 31145586
[TBL] [Abstract][Full Text] [Related]
13. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.
Boerwinkle AH; Gordon BA; Wisch J; Flores S; Henson RL; Butt OH; McKay N; Chen CD; Benzinger TLS; Fagan AM; Handen BL; Christian BT; Head E; Mapstone M; Rafii MS; O'Bryant S; Lai F; Rosas HD; Lee JH; Silverman W; Brickman AM; Chhatwal JP; Cruchaga C; Perrin RJ; Xiong C; Hassenstab J; McDade E; Bateman RJ; Ances BM; ;
Lancet Neurol; 2023 Jan; 22(1):55-65. PubMed ID: 36517172
[TBL] [Abstract][Full Text] [Related]
14. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome.
Tatebe H; Kasai T; Ohmichi T; Kishi Y; Kakeya T; Waragai M; Kondo M; Allsop D; Tokuda T
Mol Neurodegener; 2017 Sep; 12(1):63. PubMed ID: 28866979
[TBL] [Abstract][Full Text] [Related]
15. Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease.
Stevenson-Hoare J; Heslegrave A; Leonenko G; Fathalla D; Bellou E; Luckcuck L; Marshall R; Sims R; Morgan BP; Hardy J; de Strooper B; Williams J; Zetterberg H; Escott-Price V
Brain; 2023 Feb; 146(2):690-699. PubMed ID: 35383826
[TBL] [Abstract][Full Text] [Related]
16. Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
Rafii MS; Donohue MC; Matthews DC; Muranevici G; Ness S; O'Bryant SE; Rissman RA
J Alzheimers Dis; 2019; 70(1):131-138. PubMed ID: 31156181
[TBL] [Abstract][Full Text] [Related]
17. Plasma Biomarkers of Alzheimer's Disease in African Americans.
Deniz K; Ho CCG; Malphrus KG; Reddy JS; Nguyen T; Carnwath TP; Crook JE; Lucas JA; Graff-Radford NR; Carrasquillo MM; Ertekin-Taner N
J Alzheimers Dis; 2021; 79(1):323-334. PubMed ID: 33252078
[TBL] [Abstract][Full Text] [Related]
18. Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer's disease dementia in Chinese individuals.
Sun Q; Ni J; Wei M; Long S; Li T; Fan D; Lu T; Shi J; Tian J
Front Aging Neurosci; 2022; 14():963845. PubMed ID: 36062146
[TBL] [Abstract][Full Text] [Related]
19. Blood-Based ATN Biomarkers of Alzheimer's Disease: A Meta-Analysis.
Koychev I; Jansen K; Dette A; Shi L; Holling H
J Alzheimers Dis; 2021; 79(1):177-195. PubMed ID: 33252080
[TBL] [Abstract][Full Text] [Related]
20. Plasma Levels of Amyloid-β Peptides and Tau Protein in Mexican Patients with Alzheimer's Disease.
Castillo-Mendieta T; Arana-Lechuga Y; Campos-Peña V; Sosa AL; Orozco-Suarez S; Pinto-Almazán R; Segura-Uribe J; Javier Rodríguez-Sánchez de Tagle A; Ruiz-Sánchez E; Guerra-Araiza C
J Alzheimers Dis; 2021; 82(s1):S271-S281. PubMed ID: 34151786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
